Publications

  1. Brajkovic M, Nikolic S, Popadic V, Milic N, Rajovic N, Nikolic N, Sekulic A, Brankovic M, Stjepanovic M, Popevic S, Milovanovic B, Zdravkovic M. Can Galectin-3 Be Used as a Predictor of Obstructive Sleep Apnea Severity: Insights from High-Volume Patient Single Center. Diagnostics (Basel). 2025 Feb 5; 15 (3) Epub 2025 Feb 05
    View PubMed
  2. Nassir S, Yousif M, Li X, Severson KJ, Hughes A, Kechter J, Hwang A, Boudreaux B, Bhullar P, Zhang N, Butterfield RJ, Ma T, Leibovit-Reiben Z, Stockard A, Ogbaudu E, Costello CM, Nelson SA, DiCaudo DJ, Sekulic A, Baum CL, Pittelkow MR, Mangold AR. Multiomic Sequencing of Intermediate- to High-Risk Cutaneous Squamous Cell Carcinoma Identifies Critical Genes and Expression Patterns Associated with Disease and Poor Outcomes. J Invest Dermatol. 2025 Jan 28 [Epub ahead of print]
    View PubMed
  3. Bandel LA, Vierkant RA, Kruisselbrink TM, Bublitz ML, Wilson TA, Armasu SM, Egan JB, Presutti RJ, Samadder NJJ, Sekulic A, Olson RJ, Tan-Arroyo J, Morales-Rosado JA, Klee EW, Ferber MJ, Kemppainen JL, Anderson JL, Bidwell JS, Wick JJ, Ortega VE, Bobo WV, Pichurin PN, Mcmillan JM, Weaver DM, Riegert-Johnson DL, Cera AM, Boucher LM, Kullo IJ, Mantia SK, Jones MT, Larson NB, Luehrs TC, Leitzke JW, Sicotte H, Tian S, Stavlund JR, Pacyna JE, Sharp RR, Asabere AA, Lu J, McAllister TM, Walker TS, Stewart AK, Farrugia G, Lazaridis KN. Mayo Clinic Tapestry Study: A Large-Scale Decentralized Whole Exome Sequencing Study for Clinical Practice, Research Discovery, and Genomic Education. Mayo Clin Proc. 2024 Nov 5 Epub 2024 Nov 05
    View PubMed
  4. Hughes AN, Li X, Lehman JS, Nelson SA, DiCaudo DJ, Mudappathi R, Hwang A, Kechter J, Pittelkow MR, Mangold AR, Sekulic A. Drug Repurposing Using Molecular Network Analysis Identifies Jak as Targetable Driver in Necrobiosis Lipoidica. JID Innov. 2024 Nov; 4 (6):100296 Epub 2024 June 26
    View PubMed
  5. Farina JM, Olson RJ, Dhamija R, Bofferding A, Sekulic A, Egan JB, Jaroszewski DE. The Complexity of Familial Inheritance in Pectus Excavatum: A Ten-Family Exome Sequencing Analysis. Genes (Basel). 2024 Nov 1; 15 (11) Epub 2024 Nov 01
    View PubMed
  6. Hwang AS, Kechter JA, Li X, Hughes A, Severson KJ, Boudreaux B, Bhullar P, Nassir S, Yousif M, Zhang N, Butterfield RJ, Nelson S, Xing X, Tsoi LC, Zunich S, Sekulic A, Pittelkow M, Gudjonsson JE, Mangold A. Topical Ruxolitinib in the Treatment of Necrobiosis Lipoidica: A Prospective, Open-Label Study. J Invest Dermatol. 2024 Sep; 144 (9):1994-2001.e4 Epub 2024 Feb 27
    View PubMed
  7. Samadder NJ, Gay E, Lindpere V, Bublitz ML, Bandel LA, Armasu SM, Vierkant RA, Ferber MJ, Klee EW, Larson NB, Kruisselbrink TM, Egan JB, Kemppainen JL, Bidwell JS, Anderson JL, McAllister TM, Walker TS, Kunze KL, Golafshar MA, Klint MA, Presutti RJ, Bobo WV, Sekulic A, Summer-Bolster JM, Willman CL, Lazaridis KN. Exome Sequencing Identifies Carriers of the Autosomal Dominant Cancer Predisposition Disorders Beyond Current Practice Guideline Recommendations. JCO Precis Oncol. 2024 Jul; 8:e2400106
    View PubMed
  8. Peris K, Inocencio TJ, Stratigos AJ, Lewis KD, Eroglu Z, Chang ALS, Ivanescu C, Sekulic A, Fury MG, Chen CI, Quek RGW. Health-related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial. Cancer Med. 2024 Jul; 13 (14):e7360
    View PubMed
  9. Lewis KD, Peris K, Sekulic A, Stratigos AJ, Dunn L, Eroglu Z, Chang ALS, Migden MR, Yoo SY, Mohan K, Coates E, Okoye E, Bowler T, Baurain JF, Bechter O, Hauschild A, Butler MO, Hernandez-Aya L, Licitra L, Neves RI, Ruiz ES, Seebach F, Lowy I, Goncalves P, Fury MG. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors. Ann Oncol. 2024 Feb; 35 (2):221-228 Epub 2023 Dec 09
    View PubMed
  10. Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Fernandez Orland A, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Yoo SY, Okoye E, Bassukas I, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Inocencio TJ, Chen CI, LaFontaine PR, Seebach F, Lowy I, Fury MG. Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up. J Am Acad Dermatol. 2024 Feb; 90 (2):414-418 Epub 2023 Oct 14
    View PubMed
  11. Schmults CD, Blitzblau R, Aasi SZ, Alam M, Amini A, Bibee K, Bolotin D, Bordeaux J, Chen PL, Contreras CM, DiMaio D, Donigan JM, Farma JM, Ghosh K, Harms K, Ho AL, Lukens JN, Manber S, Mark L, Medina T, Nehal KS, Nghiem P, Olino K, Park S, Patel T, Puzanov I, Rich J, Sekulic A, Shaha AR, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu YG, Yu S, Yusuf M, McCullough B, Espinosa S. NCCN Guidelines(R) Insights: Merkel Cell Carcinoma, Version 1.2024. J Natl Compr Canc Netw. 2024 Jan; 22 (1D):e240002
    View PubMed
  12. Stratigos AJ, Chen CI, Ivanescu C, Lewis KD, Peris K, Bechter O, Harnett J, Mastey V, Reaney M, Daskalopoulou C, LaFontaine PR, Konidaris G, Bury D, Yoo SY, Mohan K, Coates E, Bowler T, Fury MG, Sekulic A. Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trial. Future Oncol. 2024; 20 (30):2249-2258 Epub 2024 July 29
    View PubMed
  13. Premuzic V, Stambolija V, Lozic M, Kovacevic J, Prelevic V, Peklic M, Scap M, Sekulic A, Basic-Jukic N, Mihaljevic S, Kashani KB. The effect of different anesthetics on the incidence of AKI and AKD after neurosurgical procedures. PLoS One. 2024; 19 (12):e0315295 Epub 2024 Dec 31
    View PubMed
  14. Schmults CD, Blitzblau R, Aasi SZ, Alam M, Amini A, Bibee K, Bordeaux J, Chen PL, Contreras CM, DiMaio D, Donigan JM, Farma JM, Ghosh K, Harms K, Ho AL, Lukens JN, Mark L, Medina T, Nehal KS, Nghiem P, Olino K, Park S, Patel T, Puzanov I, Rich J, Sekulic A, Shaha AR, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu YG, Yu S, Yusuf M, McCullough B, Espinosa S. Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Nov; 21 (11):1181-1203
    View PubMed
  15. Brajkovic M, Vukcevic M, Nikolic S, Dukic M, Brankovic M, Sekulic A, Popadic V, Stjepanovic M, Radojevic A, Markovic-Denic L, Rajovic N, Milic N, Tanasilovic S, Todorovic Z, Zdravkovic M. The Predictive Value of Risk Factors and Prognostic Scores in Hospitalized COVID-19 Patients. Diagnostics (Basel). 2023 Aug 11; 13 (16)
    View PubMed
  16. National Institute for Health and Care Research Global Health Research Unit on Global Surgery. Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries. Br J Surg. 2023 Jun 12; 110 (7):804-817
    View PubMed
  17. Budhraja KK, McDonald BR, Stephens MD, Contente-Cuomo T, Markus H, Farooq M, Favaro PF, Connor S, Byron SA, Egan JB, Ernst B, McDaniel TK, Sekulic A, Tran NL, Prados MD, Borad MJ, Berens ME, Pockaj BA, LoRusso PM, Bryce A, Trent JM, Murtaza M. Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancer. Sci Transl Med. 2023 Jan 11; 15 (678):eabm6863
    View PubMed
  18. Harvey JA, Severson KJ, Brumfiel CM, Patel MH, Butterfield RJ, Nelson SA, Sekulic A, Pittelkow MR, Mangold AR. Necrobiosis lipoidica-associated cutaneous malignancy. J Am Acad Dermatol. 2022 Jun; 86 (6):1428-1429 Epub 2021 June 18
    View PubMed
  19. Severson KJ, Patel MH, Brumfiel CM, Breen I, Butterfield RJ, Nelson SA, Sekulic A, Pittelkow MR, Mangold AR. Comorbidities and diabetic complications in patients with necrobiosis lipoidica. J Am Acad Dermatol 2022 Apr; 86 (4):891-894 Epub 2021 Mar 17
    View PubMed
  20. Sekulic A, Yoo S, Kudchadkar R, Guillen J, Rogers G, Chang ALS, Guenthner S, Raskin B, Dawson K, Mun Y, Chu L, McKenna E, Lacouture M. Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry. PLoS One. 2022; 17 (1):e0262151 Epub 2022 Jan 14
    View PubMed
  21. Lewis KD, Peris K, Sekulic A, Stratigos AJ, Dunn L, Eroglu Z, Chang ALS, Migden MR, Yoo SY, Mohan K, Coates E, Okoye E, Baurain J, Bechter O, Hauschild A, Butler MO, Hernandez-Aya L, Licitra L, Neves RI, Ruiz ES, Seebach F, Lowy I, Goncalves P, Fury MG. Primary analysis of phase 2 results for cemiplimab in patients with mBCC who progressed on or were intolerant to hedgehog inhibitors. Journal of Oncology Navigation & Survivorship. 2022; 13 (11):387-8
  22. Schmults CD, Blitzblau R, Aasi SZ, Alam M, Andersen JS, Baumann BC, Bordeaux J, Chen PL, Chin R, Contreras CM, DiMaio D, Donigan JM, Farma JM, Ghosh K, Grekin RC, Harms K, Ho AL, Holder A, Lukens JN, Medina T, Nehal KS, Nghiem P, Park S, Patel T, Puzanov I, Scott J, Sekulic A, Shaha AR, Srivastava D, Stebbins W, Thomas V, Xu YG, McCullough B, Dwyer MA, Nguyen MQ. NCCN Guidelines(R) Insights: Squamous Cell Skin Cancer, Version 1.2022. J Natl Compr Canc Netw. 2021 Dec; 19 (12):1382-1394
    View PubMed
  23. Patel MH, Brumfiel CM, Severson KJ, DiCaudo DJ, Nelson SA, Butterfield RJ, Zhang N, Baum C, Sekulic A, Mangold AR. The prognostic value of inositol polyphosphate 5-phosphatase in cutaneous squamous cell carcinoma in the general population. Int J Dermatol 2021 Oct; 60 (10):e427-e429 Epub 2021 Apr 16
    View PubMed
  24. Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Orland AF, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Li S, Yoo SY, Mohan K, Coates E, Jankovic V, Fiaschi N, Okoye E, Bassukas ID, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Seebach F, Thurston G, Weinreich DM, Yancopoulos GD, Lowy I, Bowler T, Fury MG. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021 Jun; 22 (6):848-857 Epub 2021 May 14
    View PubMed
  25. Halperin RF, Hegde A, Lang JD, Raupach EA, Legendre C, Liang WS, LoRusso PM, Sekulic A, Sosman JA, Trent JM, Rangasamy S, Pirrotte P, Schork NJ, C4RCD Research Group. Improved methods for RNAseq-based alternative splicing analysis. Sci Rep. 2021 May 24; 11 (1):10740
    View PubMed
  26. Samadder NJ, Riegert-Johnson D, Boardman L, Rhodes D, Wick M, Okuno S, Kunze KL, Golafshar M, Uson PLS Jr, Mountjoy L, Ertz-Archambault N, Patel N, Rodriguez EA, Lizaola-Mayo B, Lehrer M, Thorpe CS, Yu NY, Esplin ED, Nussbaum RL, Sharp RR, Azevedo C, Klint M, Hager M, Macklin-Mantia S, Bryce AH, Bekaii-Saab TS, Sekulic A, Stewart AK. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. JAMA Oncol. 2021 Feb 1; 7 (2):230-237
    View PubMed
  27. LoRusso PM, Sekulic A, Sosman JA, Liang WS, Carpten J, Craig DW, Solit DB, Bryce AH, Kiefer JA, Aldrich J, Nasser S, Halperin R, Byron SA, Pilat MJ, Boerner SA, Durecki D, Hendricks WPD, Enriquez D, Izatt T, Keats J, Legendre C, Markovic SN, Weise A, Naveed F, Schmidt J, Basu GD, Sekar S, Adkins J, Tassone E, Sivaprakasam K, Zismann V, Calvert VS, Petricoin EF, Fecher LA, Lao C, Eder JP, Vogelzang NJ, Perlmutter J, Gorman M, Manica B, Fox L, Schork N, Zelterman D, DeVeaux M, Joseph RW, Cowey CL, Trent JM. Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. PLoS One. 2021; 16 (4):e0248097 Epub 2021 Apr 07
    View PubMed
  28. Baughn LB, Sharma N, Elhaik E, Sekulic A, Bryce AH, Fonseca R. Targeting TMPRSS2 in SARS-CoV-2 Infection. Mayo Clin Proc. 2020 Sep; 95 (9):1989-1999 Epub 2020 July 19
    View PubMed
  29. Maly CJ, Cumsky HJL, Costello CM, Schmidt JE, Butterfield RJ, Zhang N, DiCaudo DJ, Nelson SA, Smith ML, Ochoa SA, Baum CL, Nagel TH, Pittelkow MR, Sekulic A, Mangold AR. Prognostic value of inositol polyphosphate-5-phosphatase expression in recurrent and metastatic cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2020 Apr; 82 (4):846-853 Epub 2019 Aug 19
    View PubMed
  30. Chandrashekar P, Ahmadinejad N, Wang J, Sekulic A, Egan JB, Asmann YW, Kumar S, Maley C, Liu L. Somatic selection distinguishes oncogenes and tumor suppressor genes. Bioinformatics. 2020 Mar 1; 36 (6):1712-1717
    View PubMed
  31. DeLeon TT, Almquist DR, Kipp BR, Langlais BT, Mangold A, Winters JL, Kosiorek HE, Joseph RW, Dronca RS, Block MS, McWilliams RR, Kottschade LA, Rumilla KM, Voss JS, Seetharam M, Sekulic A, Markovic SN, Bryce AH. Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. PLoS One. 2020; 15 (3):e0230306 Epub 2020 Mar 20
    View PubMed
  32. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A, ERIVANCE BCC Investigators. Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2019 Apr 18; 19 (1):366
    View PubMed
  33. Cumsky HJL, Costello CM, Zhang N, Butterfield R, Buras MR, Schmidt JE, Drenner K, Nelson SA, Ochoa SA, Baum CL, Pittelkow MR, DiCaudo DJ, Sekulic A, Mangold AR. The prognostic value of inositol polyphosphate 5-phosphatase in cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2019 Mar; 80 (3):626-632.e1 Epub 2018 Oct 22
    View PubMed
  34. Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Meyskens FL Jr, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019 Jan 1; 125 (1):18-44 Epub 2018 Oct 03
    View PubMed
  35. Mangold AR, Cumsky HJL, Costello CM, Xie DY, Buras MR, Nelson SA, DiCaudo DJ, Sekulic A, Pittelkow MR. Clinical and histopathologic features of paraneoplastic granuloma annulare in association with solid organ malignancies: A case-control study. J Am Acad Dermatol. 2018 Nov; 79 (5):913-920.e1 Epub 2018 June 18
    View PubMed
  36. Hendricks WPD, Zismann V, Sivaprakasam K, Legendre C, Poorman K, Tembe W, Perdigones N, Kiefer J, Liang W, DeLuca V, Stark M, Ruhe A, Froman R, Duesbery NS, Washington M, Aldrich J, Neff MW, Huentelman MJ, Hayward N, Brown K, Thamm D, Post G, Khanna C, Davis B, Breen M, Sekulic A, Trent JM. Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. PLoS Genet. 2018 Sep; 14 (9):e1007589 Epub 2018 Sept 06
    View PubMed
  37. Markus H, Contente-Cuomo T, Farooq M, Liang WS, Borad MJ, Sivakumar S, Gollins S, Tran NL, Dhruv HD, Berens ME, Bryce A, Sekulic A, Ribas A, Trent JM, LoRusso PM, Murtaza M. Evaluation of pre-analytical factors affecting plasma DNA analysis. Sci Rep. 2018 May 9; 8 (1):7375 Epub 2018 May 09
    View PubMed
  38. Lang JD, Hendricks WPD, Orlando KA, Yin H, Kiefer J, Ramos P, Sharma R, Pirrotte P, Raupach EA, Sereduk C, Tang N, Liang WS, Washington M, Facista SJ, Zismann VL, Cousins EM, Major MB, Wang Y, Karnezis AN, Sekulic A, Hass R, Vanderhyden BC, Nair P, Weissman BE, Huntsman DG, Trent JM. Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition. Clin Cancer Res. 2018 Apr 15; 24(8):1932-1943. Epub 2018 Feb 09.
    View PubMed
  39. Kim JYS, Kozlow JH, Mittal B, Moyer J, Olenecki T, Rodgers P, Work Group//Invited Reviewers. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018 Mar; 78 (3):560-578 Epub 2018 Jan 10
    View PubMed
  40. Kim JYS, Baum C, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P, Work Group//Invited Reviewers, Miller A, Sekulic A. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018 Mar; 78 (3):540-559 Epub 2018 Jan 10
    View PubMed
  41. Ding KF, Petricoin EF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ. Nonlinear mixed effects dose response modeling in high throughput drug screens: application to melanoma cell line analysis. Oncotarget. 2018 Jan 12; 9 (4):5044-5057 Epub 2017 Dec 15
    View PubMed
  42. Ding KF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ. Network Rewiring in Cancer: Applications to Melanoma Cell Lines and the Cancer Genome Atlas Patients. Front Genet. 2018; 9:228 Epub 2018 July 10
    View PubMed
  43. Yang YW, Macdonald JB, Nelson SA, Sekulic A. Treatment of vismodegib-associated muscle cramps with cyclobenzaprine: A retrospective review. J Am Acad Dermatol 2017 Dec; 77 (6):1170-1172
    View PubMed
  44. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A, ERIVANCE BCC Investigators. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017 May 16; 17 (1):332
    View PubMed
  45. Ding KF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ. Analysis of variability in high throughput screening data: applications to melanoma cell lines and drug responses. Oncotarget. 2017 Apr 25; 8: (17)27786-27799.
    View PubMed
  46. Liang WS, Hendricks W, Kiefer J, Schmidt J, Sekar S, Carpten J, Craig DW, Adkins J, Cuyugan L, Manojlovic Z, Halperin RF, Helland A, Nasser S, Legendre C, Hurley LH, Sivaprakasam K, Johnson DB, Crandall H, Busam KJ, Zismann V, Deluca V, Lee J, Sekulic A, Ariyan CE, Sosman J, Trent J. Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma. Genome Res. 2017 Apr; 27 (4):524-532
    View PubMed
  47. Chang AL, Lewis KD, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A. Safety and efficacy of vismodegib in patients aged >/=65 years with advanced basal cell carcinoma. Oncotarget. 2016 Nov 15; 7 (46):76118-76124
    View PubMed
  48. Kang HJ, Cui Y, Yin H, Scheid A, Hendricks WPD, Schmidt J, Sekulic A, Kong D, Trent JM, Gokhale V, Mao H, Hurley LH. A Pharmacological Chaperone Molecule Induces Cancer Cell Death by Restoring Tertiary DNA Structures in Mutant hTERT Promoters. J Am Chem Soc. 2016 Oct 19; 138 (41):13673-13692 Epub 2016 Oct 05
    View PubMed
  49. Lacouture ME, Dreno B, Ascierto PA, Dummer R, Basset-Seguin N, Fife K, Ernst S, Licitra L, Neves RI, Peris K, Puig S, Sokolof J, Sekulic A, Hauschild A, Kunstfeld R. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. Oncologist. 2016 Oct; 21 (10):1218-1229 Epub 2016 Aug 10
    View PubMed
  50. Chang AL, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis. 2016 Sep 1; 11 (1):120 Epub 2016 Sept 01
    View PubMed
  51. Mangold AR, Skinner R, Dueck AC, Sekulic A, Pockaj BA. Risk Factors Predicting Positive Margins at Primary Wide Local Excision of Cutaneous Melanoma. Dermatol Surg. 2016 May; 42 (5):646-52
    View PubMed
  52. Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossman K, Higgins SA, Ho AL, Lewis KD, Lydiatt DD, Nehal KS, Nghiem P, Olsen EA, Schmults CD, Sekulic A, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Wong SL, Zic JA, Hoffmann KG, Engh A. Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 May; 14: (5)574-97.
    View PubMed
  53. Mangold AR, DiCaudo DJ, Blair JE, Sekulic A. Chronic interstitial granulomatous dermatitis in coccidioidomycosis. Br J Dermatol. 2016 Apr; 174 (4):881-884 Epub 2016 Feb 03
    View PubMed
  54. Sekulic A, Von Hoff D. Hedgehog Pathway Inhibition. Cell. 2016 Feb 25; 164 (5):831
    View PubMed
  55. LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, Liang WS, Hunsberger S, Redman BG, Markovic SN, Sekulic A, Bryce AH, Joseph RW, Cowey CL, Fecher LA, Sosman JA, Chapman PB, Schwartz GK, Craig DW, Carpten JD, Trent JM. Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. Mol Cancer Ther. 2015 Aug; 14 (8):1962-71 Epub 2015 June 10
    View PubMed
  56. Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang ALS, Dirix L, Hou J, Yue H, Hauschild A. A pivotal ERIVANCE BCC study: A 12-month update of efficacy and safety of Vismodegib in advanced basal cell carcinoma (in press). J Amer Acad Dermatol. 2015 Jul.
  57. Sekulic A, Tang J, Rogers G, Olenicki T, Lacouture M, Kudchadkar R, Yoo S, Guillen J, Mun Y, Chen D, Flick D. RegiSONIC: a prospective observational study of treatment in advanced basal cell carcinoma (aBCC) and basal cell carcinoma nevus syndrome (BCCNS) patient (in press). J Amer Acad Dermatol. 2015 Jul.
  58. Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Dirix L, Hou J, Yue H, Hauschild A, ERIVANCE BCC investigators. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015 Jun; 72 (6):1021-6.e8
    View PubMed
  59. Sekulic A, Liang WS, Tembe W, Izatt T, Kruglyak S, Kiefer JA, Cuyugan L, Zismann V, Legendre C, Pittelkow MR, Gohmann JJ, De Castro FR, Trent J, Carpten J, Craig DW, McDaniel TK. Personalized treatment of Sezary syndrome by targeting a novel CTLA4:CD28 fusion. Mol Genet Genomic Med. 2015 Mar; 3 (2):130-6 Epub 2014 Nov 27
    View PubMed
  60. Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015 Feb; 72 (2):221-36; quiz 237-8
    View PubMed
  61. Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol. 2015 Feb; 72 (2):203-18; quiz 219-20
    View PubMed
  62. Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WP, Corneveaux JJ, Barrett MT, Shumansky K, Yang Y, Shah SP, Prentice LM, Marra MA, Kiefer J, Zismann VL, McEachron TA, Salhia B, Prat J, D'Angelo E, Clarke BA, Pressey JG, Farley JH, Anthony SP, Roden RB, Cunliffe HE, Huntsman DG, Trent JM. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet. 2014 May; 46 (5):427-9 Epub 2014 Mar 23
    View PubMed
  63. McCusker M, Basset-Seguin N, Dummer R, Lewis K, Schadendorf D, Sekulic A, Hou J, Wang L, Yue H, Hauschild A. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer. 2014 Mar; 50 (4):774-83 Epub 2014 Jan 09
    View PubMed
  64. Ramos P, Karnezis AN, Hendricks WP, Wang Y, Tembe W, Zismann VL, Legendre C, Liang WS, Russell ML, Craig DW, Farley JH, Monk BJ, Anthony SP, Sekulic A, Cunliffe HE, Huntsman DG, Trent JM. Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Rare Dis. 2014; 2 (1):e967148 Epub 2014 Nov 03
    View PubMed
  65. Sekulic A, Mangold AR, Northfelt DW, LoRusso PM. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway. Curr Opin Oncol. 2013 May; 25(3):218-23.
    View PubMed
  66. Barrett MT, Lenkiewicz E, Evers L, Holley T, Ruiz C, Bubendorf L, Sekulic A, Ramanathan RK, Von Hoff DD. Clonal evolution and therapeutic resistance in solid tumors. Front Pharmacol. 2013; 4:2 Epub 2013 Jan 28
    View PubMed
  67. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 7; 366 (23):2171-9
    View PubMed
  68. Egnatios GL, Dueck AC, Macdonald JB, Laman SD, Warschaw KE, DiCaudo DJ, Nemeth SA, Sekulic A, Gray RJ, Wasif N, Pockaj BA. The impact of biopsy technique on upstaging, residual disease, and outcome in cutaneous melanoma. Am J Surg. 2011 Dec; 202 (6):771-7; discussion 777-8 Epub 2011 Oct 13
    View PubMed
  69. Macdonald JB, Dueck AC, Gray RJ, Wasif N, Swanson DL, Sekulic A, Pockaj BA. Malignant melanoma in the elderly: different regional disease and poorer prognosis. J Cancer. 2011; 2:538-43 Epub 2011 Nov 01
    View PubMed
  70. Stucky CC, Gray RJ, Dueck AC, Wasif N, Laman SD, Sekulic A, Pockaj BA. Risk factors associated with local and in-transit recurrence of cutaneous melanoma. Am J Surg. 2010 Dec; 200 (6):770-4; discussion 774-5
    View PubMed
  71. Sekulic A, Colgan MB, Davis MD, DiCaudo DJ, Pittelkow MR. Activating BRAF mutations in eruptive melanocytic naevi. Br J Dermatol. 2010 Nov; 163(5):1095-8.
    View PubMed
  72. Sekulic A, Kim SY, Hostetter G, Savage S, Einspahr JG, Prasad A, Sagerman P, Curiel-Lewandrowski C, Krouse R, Bowden GT, Warneke J, Alberts DS, Pittelkow MR, DiCaudo D, Nickoloff BJ, Trent JM, Bittner M. Loss of inositol polyphosphate 5-phosphatase is an early event in development of cutaneous squamous cell carcinoma. Cancer Prev Res (Phila). 2010 Oct; 3 (10):1277-83 Epub 2010 Sept 28
    View PubMed
  73. Jatoi A, Thrower A, Sloan JA, Flynn PJ, Wentworth-Hartung NL, Dakhil SR, Mattar BI, Nikcevich DA, Novotny P, Sekulic A, Loprinzi CL. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist. 2010; 15 (9):1016-22 Epub 2010 Aug 26
    View PubMed
  74. Markovic SN, Erickson LA, Flotte TJ, Kottschade LA, McWilliams RR, Jakub JW, Farley DR, Tran NV, Schild SE, Olivier KR, Vuk-Pavlovic S, Sekulic A, Weenig RH, Pulido JS, Quevedo JF, Vile RG, Wiseman GA, Stoian I, Pittelkow MR, Melanoma Study. Metastatic malignant melanoma. G Ital Dermatol Venereol. 2009 Feb; 144(1):1-26.
    View PubMed
  75. Carpenter S, Pockaj B, Dueck A, Gray R, Kurtz D, Sekulic A, Casey W. Factors influencing time between biopsy and definitive surgery for malignant melanoma: do they impact clinical outcome? Am J Surg. 2008 Dec; 196 (6):834-42; discussion 842-3
    View PubMed
  76. Sekulic A, Haluska P Jr, Miller AJ, Genebriera De Lamo J, Ejadi S, Pulido JS, Salomao DR, Thorland EC, Vile RG, Swanson DL, Pockaj BA, Laman SD, Pittelkow MR, Markovic SN, Melanoma Study Group of Mayo Clinic Cancer Center. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc. 2008 Jul; 83 (7):825-46
    View PubMed
  77. Sekulic A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 2000 Jul 1; 60 (13):3504-13
    View PubMed
  78. Hosoi H, Dilling MB, Liu LN, Danks MK, Shikata T, Sekulic A, Abraham RT, Lawrence JC Jr, Houghton PJ. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol. 1998 Nov; 54(5):815-24.
    View PubMed
  79. Kennedy AP, Sekulic A, Irvin BJ, Nilson AE, Dilworth SM, Abraham RT. Polyomavirus middle T antigen as a probe for T cell antigen receptor-coupled signaling pathways. J Biol Chem. 1998 May 8; 273 (19):11505-13
    View PubMed
  80. Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, Lawrence JC, Abraham RT. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science. 1997 Jul 4; 277(5322):99-101.
    View PubMed